Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.
We analyzed >70 recent data sets to compare the serogroups causing invasive pneumococcal disease (IPD) with those represented in conjugate vaccine formulations. Five to 8 and 10-11 serogroups comprise at least 75% of pneumococcal isolates from young children and older children/adults, respectively, in each geographic region. Serogroups in the 7-valent formulation (4, 6, 9, 14, 18, 19, and 23) cause 70%-88% of IPD in young children in the United States and Canada, Oceania, Africa, and Europe, and <65% in Latin America and Asia. Serogroups in the 9-valent formulation (7-valent+1, 5) cause 80%-90% of IPD in each region except Asia (66%). Serogroup 1 accounts for >6% of IPD in each region, including Europe, except the United States and Canada and Oceania. In contrast, several serogroups not found in 7-, 9-, and 11-valent conjugate formulations are significant causes of disease in older children/adults. Nevertheless, each conjugate formulation could prevent a substantial IPD burden in each region and age group.
Hausdorff
W P
WP
Wyeth-Lederle Vaccines, West Henrietta and Pearl River, NY 14586, USA. Hausdowp@war.wyeth.com
Bryant
J
J
Paradiso
P R
PR
Siber
G R
GR
D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D001428:Bacterial Vaccines / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000382:microbiology* / Q000517:prevention & control*; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification / Q000276:immunology* / Q000302:isolation & purification / Q000472:pathogenicity*; D018074:Vaccines, Conjugate / Q000276:immunology
D001428:Bacterial Vaccines; D018074:Vaccines, Conjugate